Literature DB >> 21295684

MDM2 and MDMX in cancer and development.

Jean-Christophe Marine1.   

Abstract

The p53 tumor suppressor pathway is active in cells that are subjected to stress and/or damaged, where it promotes cell cycle arrest or apoptosis. In contrast, in normal cells that are not exposed to stress signals and in tumor cells p53 is tightly kept in check or completely silenced. In most, if not all, tumor cells p53 is indeed inactivated by mutations in the p53 locus or by alternative, yet unclear, mechanisms that impinge directly or indirectly on p53 function. Recent biochemical and genetic data indicate that tumor cells hijack and enforce some of the mechanisms used by normal cells to restrain p53 function. This is best illustrated by the aberrant expression in tumor cells of MDM2 and MDMX (or MDM4), two structurally related proteins that play a critical role in maintaining p53 in an OFF state under normal conditions, but in particular in embryonic and stem cells. These advances and their potential implications for the development of new cancer therapeutic strategies form the focus of this chapter.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295684     DOI: 10.1016/B978-0-12-380916-2.00003-6

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  19 in total

1.  Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors:  Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal:  Blood       Date:  2012-08-07       Impact factor: 22.113

2.  Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity.

Authors:  Dingding Shi; Wei Gu
Journal:  Genes Cancer       Date:  2012-03

3.  The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Authors:  Min Lu; Lijuan Xia; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

Review 4.  Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Authors:  Bernard Leroy; Mandy L Ballinger; Fanny Baran-Marszak; Gareth L Bond; Antony Braithwaite; Nicole Concin; Lawrence A Donehower; Wafik S El-Deiry; Pierre Fenaux; Gianluca Gaidano; Anita Langerød; Eva Hellstrom-Lindberg; Richard Iggo; Jacqueline Lehmann-Che; Phuong L Mai; David Malkin; Ute M Moll; Jeffrey N Myers; Kim E Nichols; Sarka Pospisilova; Patricia Ashton-Prolla; Davide Rossi; Sharon A Savage; Louise C Strong; Patricia N Tonin; Robert Zeillinger; Thorsten Zenz; Joseph F Fraumeni; Peter E M Taschner; Pierre Hainaut; Thierry Soussi
Journal:  Cancer Res       Date:  2017-03-15       Impact factor: 12.701

5.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

6.  Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Authors:  Michael Dewaele; Tommaso Tabaglio; Karen Willekens; Marco Bezzi; Shun Xie Teo; Diana H P Low; Cheryl M Koh; Florian Rambow; Mark Fiers; Aljosja Rogiers; Enrico Radaelli; Muthafar Al-Haddawi; Soo Yong Tan; Els Hermans; Frederic Amant; Hualong Yan; Manikandan Lakshmanan; Ratnacaram Chandrahas Koumar; Soon Thye Lim; Frederick A Derheimer; Robert M Campbell; Zahid Bonday; Vinay Tergaonkar; Mark Shackleton; Christine Blattner; Jean-Christophe Marine; Ernesto Guccione
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

7.  Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

Authors:  B Bardot; R Bouarich-Bourimi; J Leemput; V Lejour; A Hamon; L Plancke; A G Jochemsen; I Simeonova; M Fang; F Toledo
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

8.  Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.

Authors:  Lei Jin; Erich M Sturgis; Yang Zhang; Zhigang Huang; Peng Wei; Wei Guo; Zhongqiu Wang; Qingyi Wei; Xicheng Song; Guojun Li
Journal:  Carcinogenesis       Date:  2013-03-18       Impact factor: 4.944

Review 9.  Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Authors:  Qin Li; Guillermina Lozano
Journal:  Clin Cancer Res       Date:  2012-12-21       Impact factor: 12.531

10.  Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Authors:  Yong S Chang; Bradford Graves; Vincent Guerlavais; Christian Tovar; Kathryn Packman; Kwong-Him To; Karen A Olson; Kamala Kesavan; Pranoti Gangurde; Aditi Mukherjee; Theresa Baker; Krzysztof Darlak; Carl Elkin; Zoran Filipovic; Farooq Z Qureshi; Hongliang Cai; Pamela Berry; Eric Feyfant; Xiangguo E Shi; James Horstick; D Allen Annis; Anthony M Manning; Nader Fotouhi; Huw Nash; Lyubomir T Vassilev; Tomi K Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.